Result of AGM

RNS Number : 9756J
Venn Life Sciences Holdings PLC
23 July 2013
 



Venn Life Sciences Holdings Plc

("Venn" or the "Company")

 

Result of AGM

 

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.

 

Enquiries:

 

Venn Life Sciences Holdings Plc


Tony Richardson, Chief Executive Officer

Tel: +353 154 99 341

Paul Foulger, Finance Director

Tel: 020 7245 1100

Orla McGuinness, Marketing Manager

Tel: +33 (0)1 30 82 67 07



Zeus Capital (Nominated Adviser and Broker)


Ross Andrews/Andrew Jones (Corporate Finance)

Tel: 0161 831 1512

John Goold (Institutional Sales)

Tel: 020 7533 7716



Walbrook PR Ltd

Tel: 020 7933 8780 or venn@walbrookpr.com

Paul McManus   

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

Additional Information:

 

About Venn Life Sciences Limited: www.vennlifesciences.com

Venn Life Sciences is a Clinical Research Organisation ("CRO") providing a suite of clinical trial management services to pharmaceutical, biotechnology and medical device organisations. With operations in France, Ireland, the Netherlands, Russia, the UK, and a branch office in Switzerland, the Venn Group also includes a Clinical Resourcing business placing experienced clinical teams and individuals on projects throughout Europe. The Company's near term objective is the expansion of its coverage to other European countries through strategic acquisitions and organic growth, offering clients a full service, multi-centred capability in Phase II-IV trials and across a range of principal disease areas.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGUOOSROWABUAR

Companies

Hvivo (HVO)
UK 100

Latest directors dealings